Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL; ZUMA-7 Investigators; Kite Members. Westin JR, et al. Among authors: mcguirk j. N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5. N Engl J Med. 2023. PMID: 37272527 Clinical Trial.
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).
Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. Hill JA, et al. Among authors: mcguirk j. medRxiv [Preprint]. 2024 Jan 25:2024.01.24.24301058. doi: 10.1101/2024.01.24.24301058. medRxiv. 2024. PMID: 38343800 Free PMC article. Preprint.
Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review.
Bellman P, Gonzalez-Lugo JD, Shahzad M, Amin MK, Khalid MF, Suleman N, Ahmed N, Singh AK, Yacoub A, Zhang D, McGuirk JP, Mushtaq MU. Bellman P, et al. Among authors: mcguirk jp. Front Oncol. 2024 Apr 11;14:1383730. doi: 10.3389/fonc.2024.1383730. eCollection 2024. Front Oncol. 2024. PMID: 38665946 Free PMC article.
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium.
Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD Jr, Lin Y. Afrough A, et al. Among authors: mcguirk jp. Blood Cancer J. 2024 Apr 12;14(1):63. doi: 10.1038/s41408-024-00993-0. Blood Cancer J. 2024. PMID: 38609386 Free PMC article. No abstract available.
Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review.
Shahzad M, Khalid MF, Amin MK, Ammad-Ud-Din M, Ilyas U, Mushtaq AH, Butt A, Anwar I, Chaudhary SG, Ahmed N, Shune L, Singh AK, Abhyankar SH, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: mcguirk jp. Hematol Oncol Stem Cell Ther. 2024 Mar 22;17(2):88-94. doi: 10.56875/2589-0646.1118. Hematol Oncol Stem Cell Ther. 2024. PMID: 38560970
Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience.
McGuirk M, Shahzad M, Amin MK, Khan MA, Bellman P, Mudaranthakam DP, DeJarnette S, Lutfi F, Ahmed N, Bansal R, Abdelhakim H, Gorsline C, Shoemaker DM, Abdallah AO, Shune L, Abhyankar SH, Singh AK, McGuirk JP, Mushtaq MU. McGuirk M, et al. Among authors: mcguirk jp. Transpl Immunol. 2024 Mar 19;84:102039. doi: 10.1016/j.trim.2024.102039. Online ahead of print. Transpl Immunol. 2024. PMID: 38513813 Free article.
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated myelodysplastic syndrome: A systematic review and meta-analysis.
Shahzad M, Iqbal Q, Tariq E, Ammad-Ud-Din M, Butt A, Mushtaq AH, Ali F, Chaudhary SG, Anwar I, Gonzalez-Lugo JD, Abdelhakim H, Ahmed N, Hematti P, Singh AK, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: mcguirk jp. Crit Rev Oncol Hematol. 2024 Apr;196:104310. doi: 10.1016/j.critrevonc.2024.104310. Epub 2024 Feb 27. Crit Rev Oncol Hematol. 2024. PMID: 38423375 Free article. Review.
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldés A, Stölzel F, Rathje K, Fischer L, Born P, Schäfer L, Albici AM, Schub N, Kfir-Erenfeld S, Assayag M, Asherie N, Wulf GG, Kharboutli S, Müller F, Shune L, Davis JA, Anwer F, Vucinic V, Platzbecker U, Ayuk F, Kröger N, Khouri J, Gurnari C, McGuirk J, Stepensky P, Abdallah AO, Fernández de Larrea C. Gagelmann N, et al. Among authors: mcguirk j. J Clin Oncol. 2024 Feb 15:JCO2302232. doi: 10.1200/JCO.23.02232. Online ahead of print. J Clin Oncol. 2024. PMID: 38358946
Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.
Ghobadi A, Munoz J, Westin JR, Locke FL, Miklos DB, Rapoport AP, Perales MA, Reagan PM, McGuirk JP, Jacobson CA, Kersten MJ, Avivi I, Peng A, Schupp M, To C, Oluwole OO. Ghobadi A, et al. Among authors: mcguirk jp. Blood Adv. 2024 Feb 5:bloodadvances.2023011532. doi: 10.1182/bloodadvances.2023011532. Online ahead of print. Blood Adv. 2024. PMID: 38315832
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
Dima D, Rashid A, Davis JA, Shune L, Abdallah AO, Li H, DeJarnette S, Khouri J, Williams L, Hashmi H, Raza S, McGuirk J, Anwer F, Ahmed N. Dima D, et al. Among authors: mcguirk j. Br J Haematol. 2024 Apr;204(4):1293-1299. doi: 10.1111/bjh.19302. Epub 2024 Jan 23. Br J Haematol. 2024. PMID: 38263627
237 results